Metagenomi Therapeutics, Inc.
MGX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MGX
Metagenomi Therapeutics, Inc. (MGX) is a preclinical-stage biotechnology company focused on developing genetic medicines, with $43.4 million in cash as of June 30, 2026, and a net loss of $27.5 million for the quarter.
Key risk: Preclinical stage risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Metagenomi Therapeutics, Inc. (MGX) is a preclinical-stage biotechnology company focused on developing genetic medicines, with $43.4 million in cash as of June 30, 2026, and a net loss of $27.5 million for the quarter.
- Cash and equivalents were $43.4 million as of June 30, 2026 [sec].
- Net loss was $27.5 million for the quarter ended June 30, 2026 [sec].
- Shareholders' equity was $195.8 million as of June 30, 2026 [sec].
- The company expects expenses to increase substantially as it advances its portfolio toward candidate nomination and preclinical trials [sec_mda · as of 2026-08-10].
What works
- Cash position of $43.4 million as of June 30, 2026, provides near-term operational runway [sec].
- Shareholders' equity of $195.8 million indicates a solid capital base relative to current losses [sec].
What to weigh
- Net loss of $27.5 million in the latest quarter reflects ongoing cash burn without approved products [sec].
- Expenses are expected to increase substantially as the company advances its preclinical pipeline, raising uncertainty about future capital needs [sec_mda · as of 2026-08-10].
- The company faces significant risks related to obtaining regulatory approval and market acceptance for any future product candidates [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had $120.7 million in cash, cash equivalents and available-for-sale marketable securities.”
SEC MD&A · August 10, 2026
Expectation of increasing expenses
“We expect our short and long-term expenses to increase substantially in connection with our ongoing activities, particularly as we advance our portfolio towards candidate nomination and preclinical trials.”
SEC MD&A · August 10, 2026
Risks & what to watch (4)›
Key risks
- Preclinical stage risk — No approved products; all candidates are in preclinical development, with no guarantee of clinical success [sec_mda · as of 2026-08-10].
- Cash burn and dilution — Net loss of $27.5M in Q2 2026; increasing expenses may require future capital raises, diluting existing shareholders [sec].
- Regulatory and reimbursement uncertainty — Future product candidates require regulatory approval and adequate reimbursement, which are uncertain [sec_mda · as of 2026-08-10].
- Competitive technology landscape — Rapidly evolving gene-editing field with many competitors; technological obsolescence is a risk [sec_mda · as of 2026-08-10].
What to watch
- Progress of preclinical pipeline toward candidate nomination and IND-enabling studies [sec_mda · as of 2026-08-10].
- Cash runway updates and any future capital-raising activities [sec_mda · as of 2026-08-10].
- Regulatory developments for gene-editing therapies that could affect the company's programs [sec_mda · as of 2026-08-10].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Metagenomi Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Metagenomi Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
18.6 months
D/E 0.54 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 6 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$8.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,115,888 | $2.8M |
| renaissance technologies llc | 787,900 | $1.1M |
| two sigma investments, lp | 496,767 | $666K |
| bridgeway capital management, llc | 395,800 | $530K |
| jacobs levy equity management, inc | 382,153 | $512K |
| geode capital management, llc | 358,200 | $480K |
| pura vida investments, llc | 264,391 | $354K |
| blackrock, inc. | 230,134 | $308K |
| wells fargo & company/mn | 202,138 | $271K |
| vanguard fiduciary trust co | 170,174 | $228K |
Showing top 10 of 46 institutional holders of Metagenomi Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 7.9%
- Days to cover
- 8.2
- Shares short
- 2,167,525
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MGX short interestFrequently asked questions
What is the AI investment thesis for Metagenomi Therapeutics, Inc.?
Metagenomi Therapeutics, Inc. (MGX) is a preclinical-stage biotechnology company focused on developing genetic medicines, with $43.4 million in cash as of June 30, 2026, and a net loss of $27.5 million for the quarter.
Who is the CEO of Metagenomi Therapeutics, Inc.?
Dr. Jian Irish M.B.A., Ph.D. is the chief executive officer of Metagenomi Therapeutics, Inc. (MGX).
Where is Metagenomi Therapeutics, Inc. headquartered?
Metagenomi Therapeutics, Inc. (MGX) is headquartered in EmeryVille, CA, United States.
What therapeutic areas does Metagenomi Therapeutics, Inc. focus on?
Metagenomi Therapeutics, Inc. develops therapies across Rare Disease, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.